IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

Company Overview

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies. This platform supports the rapid progression of drug candidates from target validation through early clinical development. IDEAYA has entered strategic collaborations with established pharmaceutical partners to expand the reach of its synthetic lethality portfolio, leveraging complementary expertise in drug discovery, development, and commercialization.

Founded in 2016 and headquartered in South San Francisco, California, IDEAYA maintains research operations in the United States and collaborates with leading academic institutions and industry organizations worldwide. The company’s management team comprises experienced biopharmaceutical executives and oncology researchers who guide its mission to deliver precision medicines to patients with high-need cancers. IDEAYA continues to build on its scientific foundation to bring forward innovative treatments that address genetically defined subsets of tumors.

Key Stats

• Today's Range: $36.07 to $36.97
• 50-Day Range: $27.60 to $40.51
• 52-Week Range: $22.09 to $40.58
• Volume: 113,408 shs
• Average Volume: 1.10 million shs
• Market Capitalization: $3.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $50.38
• Consensus Rating: Moderate Buy

IDEAYA Biosciences Stock Analysis - MarketRank™

IDEAYA Biosciences scored higher than 76% of companies evaluated by MarketBeat, and ranked 162nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

IDEAYA Biosciences has a consensus price target of $50.25, representing about 38.7% upside from its current price of $36.24.

Amount of Analyst Coverage

IDEAYA Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for IDEAYA Biosciences are expected to grow in the coming year, from ($4.10) to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEAYA Biosciences is -22.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEAYA Biosciences is -22.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IDEAYA Biosciences has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.43% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.61.

Change versus previous month

Short interest in IDEAYA Biosciences has recently decreased by 7.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEAYA Biosciences does not currently pay a dividend.

Dividend Growth

IDEAYA Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.46

News Sentiment

IDEAYA Biosciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for IDEAYA Biosciences this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for IDYA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added IDEAYA Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, IDEAYA Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $382,096.00 in company stock.

Percentage Held by Insiders

4.70% of the stock of IDEAYA Biosciences is held by insiders.

Percentage Held by Institutions

98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 8/05/2026
• Last Earnings: 8/10/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IDYA
• CIK: 1676725
• Web: www.ideayabio.com
• Phone: (650) 443-6209
• Fax: N/A
• Employees: 80
• Year Founded: 2015

Price Target and Rating

• Average Price Target for IDEAYA Biosciences: $50.38
• High Price Target: $79.00
• Low Price Target: $30.00
• Potential Upside/Downside: +38.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.81
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.70 million
• Net Margins: N/A
• Pretax Margin: -62.17%
• Return on Equity: -14.24%
• Return on Assets: -13.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.74
• Quick Ratio: 10.74

Sales & Book Value

• Annual Sales: $218.71 million
• Price / Sales: 14.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.67 per share
• Price / Book: 3.11

Miscellaneous

• Outstanding Shares: 87,860,000
• Free Float: 83,732,000
• Market Cap: $3.19 billion
• Optionable: Optionable
• Beta: -0.10